Core Insights - Chuangdong Investment announced a Pre-A round investment of tens of millions of RMB in Shenzhen Jindu Biomedical Technology Co., Ltd. (referred to as "Jindu Bio") on October 24, with Jiangxi Jin Kong participating in the investment, bringing Jindu Bio's total financing to nearly 100 million RMB to date [1] Company Overview - Jindu Bio possesses the cutting-edge global biological science model GeneLLM and has developed a one-stop biological science research platform called BioFord, along with AI products such as the AI4S Lab digital life science laboratory [1] - The core team, led by founder Dr. Jin Yongcheng, consists entirely of members from the University of Oxford, showcasing a multidisciplinary background in life sciences and artificial intelligence, which highlights the company's composite team characteristics [1] Investment Context - The investment by Chuangdong Investment aligns with its focus on the major sectors of AI and health, indicating a strategic interest in companies that integrate advanced technology with life sciences [1]